ReviewWorld journal of virology2012
Porcine reproductive and respiratory syndrome virus vaccines: Immunogenicity, efficacy and safety aspects.
Review in World journal of virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 209 citations in OpenAlex.
- Safety and efficacy of a novel European vaccine for porcine reproductive and respiratory virus in bred gilts.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2016Trial
- Safety and early onset of immunity with a novel European porcine reproductive and respiratory syndrome virus vaccine in young piglets.Canadian journal of veterinary research = Revue canadienne de recherche veterinaire · 2016Trial
- Evaluation of the contribution of the minor envelope complex glycoprotein 3 ectodomain to the porcine reproductive and respiratory syndrome virus 1 neutralizing antibody response.The Journal of general virology · 2026Article
- Comparison of porcine reproductive and respiratory syndrome modified live virus and inactivated virus vaccines against NADC34-like PRRS virus challenge in the field.Veterinary research communications · 2026Article
- Geographic Distribution and ORF5 Diversity of PRRSV-2 Variants in Midwestern U.S. Diagnostic Submissions, 2023-2025.Pathogens (Basel, Switzerland) · 2026Article
- Structural basis of porcine reproductive and respiratory syndrome virus 2 neutralization by a GP4-targeting monoclonal antibody.The Journal of general virology · 2026Article
- Protein nanoparticles assemble in plants, display antigenic viral peptides, and produce an epitope-specific immune response.The FEBS journal · 2026Article
- Serological Findings in Pigs Vaccinated AgainstVeterinary sciences · 2026Article
- AI-Based Respiratory Monitoring-Guided Evaluation of Rottlerin Therapy for PRRS in Grower-Finisher Pig Farms.Viruses · 2026Article
- Viral Vaccines as an Alternative to Antimicrobials: A Perspective from Swine Veterinarians on Challenges, Opportunities, and Future Directions.Pathogens (Basel, Switzerland) · 2025Article
- Pathogenic and transcriptomic differences among porcine reproductive and respiratory syndrome viruses from distinct lineages in piglets.Veterinary research · 2025Article
- Genetic Diversity and Temporal Shifts of Porcine Reproductive and Respiratory Syndrome Virus Type 2 (PRRSV-2) Strains in Japan (2020-2023): Evidence of Modified Live Vaccine Influence on Cluster Distribution.Epidemiologia (Basel, Switzerland) · 2025Article
- Reduction in finisher pig death rate on a farm in Japan following use of a commercial killed vaccine against porcine reproductive and respiratory syndrome virus.The Journal of veterinary medical science · 2025Article
- A centralised immunogen approach to develop a more broadly protective modified live porcine reproductive and respiratory syndrome virus 1 vaccine candidate.NPJ vaccines · 2025Article
- In Silico Designed Multi-Epitope Vaccine Based on the Conserved Fragments in Viral Proteins for Broad-Spectrum Protection Against Porcine Reproductive and Respiratory Syndrome Virus.Veterinary sciences · 2025Article
- Engineering a bivalent nanoparticle vaccine with PCV2 capsid protein and PRRSV epitopes.Journal of nanobiotechnology · 2025Article
- Epidemiological Review of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in Japan: From Discovery and Spread to Economic Losses and Future Prospects.Veterinary sciences · 2025Review
- First study to describe the prevalence and epidemiology of African swine fever, classical swine fever, porcine reproductive and respiratory syndrome and swine flu in Kazakhstan.BMC veterinary research · 2025Article
- Scalable Production of Recombinant Adeno-Associated Virus Vectors Expressing Soluble Viral Receptors for Broad-Spectrum Inhibition of Porcine Reproductive and Respiratory Syndrome Virus Type 2.Veterinary sciences · 2025Article
- Isolation and genetic characterization of a novel recombinant HP-PRRSV strain in Jiangxi Province, China.Frontiers in veterinary science · 2025Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) infection is the leading cause of economic casualty in swine industry worldwide. The virus can cause reproductive failure, respiratory disease, and growth retardation in the pigs. This review deals with current status of commercial PRRS vaccines presently used to control PRRS. The review focuses on the immunogenicity, protective efficacy and safety aspects of the vaccines. Commercial PRRS modified-live virus (MLV) vaccine elicits delayed humoral and cell-mediated immune responses following vaccination. The vaccine confers late but effective protection against genetically homologous PRRSV, and partial protection against genetically heterologous virus. The MLV vaccine is of concern for its safety as the vaccine virus can revert to virulence and cause diseases. PRRS killed virus (KV) vaccine, on the other hand, is safe but confers limited protection against either homologous or heterologous virus. The KV vaccine yet helps reduce disease severity when administered to the PRRSV-infected pigs. Although efforts have been made to improve the immunogenicity, efficacy and safety of PRRS vaccines, a better vaccine is still needed in order to protect against PRRSV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.